Crohn's Disease (CD) Epidemiology Forecast 2025-2034

Crohn’s Disease (CD), a type of inflammatory bowel disease (IBD), causes inflammation and irritation in the digestive tract. It is reported to affect 6 to 8 million people worldwide. In the United States, around 1 million individuals are estimated to have Crohn’s disease.

Crohn’s Disease (CD) Epidemiology Forecast Report Coverage

The “Crohn’s Disease (CD) Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of Crohn’s disease (CD). It projects the future incidence and prevalence rates of Crohn’s disease (CD) across various populations. The study covers age, gender, and type as major determinants of the Crohn’s disease (CD)-affected population. The report highlights patterns in the prevalence of Crohn’s disease (CD) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of Crohn’s disease (CD) in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Crohn’s Disease (CD) Overview

Crohn’s disease is one of the two main types of inflammatory bowel diseases that primarily affect the gastrointestinal tract. The exact cause of Crohn’s disease is not known but is believed to be a result of genetic, environmental, and immune system factors. Common symptoms include abdominal pain, persistent diarrhea, fatigue, weight loss, and malnutrition. Crohn's disease patients experience periods of flare-ups and remission, with symptoms varying in intensity. The condition is reported to cause intestinal strictures, fistulas, and an increased risk of colorectal cancer, among other complications.

Crohn’s Disease (CD): Treatment Overview

Existing treatment options for Crohn’s disease aim to reduce inflammation, manage symptoms, and prevent complications. Drugs like aminosalicylates (5-ASAs) are typically used for mild inflammation, especially in the colon. Corticosteroids are prescribed for short-term control of moderate to severe flare-ups. Immunomodulators, such as azathioprine or methotrexate, are also used to suppress the immune response and help maintain remission. Targeted therapies, including anti-TNF agents and newer agents like ustekinumab or vedolizumab, are increasingly being explored for Crohn's disease treatment.

Epidemiology

The Crohn’s Disease (CD) epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for Crohn’s disease (CD) by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Crohn’s disease (CD) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• An estimated 6 to 8 million people have Crohn’s disease globally, with the onset typically occurring between ages 15 and 30 and 40 and 60.
• Inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis, are estimated to affect around 1.6 million Americans, with most of the cases diagnosed before the patient reaches 35 years.
• An individual of any race or age can develop Crohn’s disease. However, the condition is more likely to develop in people who fall between the ages of 20 and 29, have a family member with inflammatory bowel disease, or belong to Jewish descent.
• Studies show that Crohn’s disease is prevalent in North America, Northern Europe, and New Zealand, with a considerably high incidence in Northern Europe and people of Jewish descent (estimated incidence 3.2 per 1000).

Country-wise Crohn’s Disease (CD) Epidemiology

The Crohn’s disease (CD) epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of Crohn’s disease (CD) varies between countries owing to differences in genetic predispositions, environmental factors, dietary patterns, access to treatment, and diagnostic practices, among others. In the United States, it is estimated that approximately 1 million people are affected by Crohn’s disease.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Crohn’s disease (CD) based on several factors.
• Crohn’s Disease (CD) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of Crohn’s disease (CD) are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of Crohn’s disease (CD) epidemiology in the 8 major markets?
• What will be the total number of patients with Crohn’s disease (CD) across the 8 major markets during the forecast period?
• What was the country-wise prevalence of Crohn’s disease (CD) in the 8 major markets in the historical period?
• Which country will have the highest number of Crohn’s disease (CD) patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of Crohn’s disease (CD) during the forecast period of 2025-2034?
• What are the currently available treatments for Crohn’s disease (CD)?
• What are the disease risks, signs, symptoms, and unmet needs of Crohn’s disease (CD)?

This product will be delivered within 3-5 business days.